2024

- Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis

- ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence

- Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations

- New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure

- Salix Announces 2024 Gastrointestinal Health Scholars Program

2023

- Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day

- The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis

- New Analysis Indicates That a Majority of Overt Hepatic Encephalopathy (OHE) Patients May Face Delays in Treatment Initiation and Gaps During Treatment for Access to Treatment Indicated to Reduce Risk for OHE Recurrence

- Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.

- Salix Pharmaceuticals Partners with Bellamy Young

- Salix Announces 2023 Gastrointestinal Health Scholars Program Winners

- Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL's International Liver Congress(TM) 2023

- Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023

- Salix Partners with the Colorectal Cancer Alliance on Community Screening Program

- New Research: More Than Half of IBS Patients Surveyed Report Waiting More Than One Year Before Discussing IBS Symptoms With Their Healthcare Provider

- Salix Announces 2023 Gastrointestinal Health Scholars Program

2022

- Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider

- Salix Will Present Rifaximin Data at AASLD's The Liver Meeting^® 2022

- Salix Will Present XIFAXAN^® (Rifaximin), TRULANCE^® (Plecanatide) and RELISTOR^® (Methylnaltrexone Bromide) Data at The American College of Gastroenterology^® 2022 Annual Scientific Meeting

- Salix Pharmaceuticals Releases Liver Health Annual Trends Report Underscoring Challenges in Caring for Growing Chronic Liver Disease and Cirrhotic Patient Population

- Salix Pharmaceuticals Applauds Implementation of K76.82 – a New ICD-10 Code for Hepatic Encephalopathy

- Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)

- Salix Announces 2022 Gastrointestinal Health Scholars Program Winners

- Salix to Share New Data from XIFAXAN^® (Rifaximin) Clinical Research at EASL's International Liver Congress™ 2022

- Salix Pharmaceuticals To Share New Data At Digestive Disease Week^® 2022

- Salix Pharmaceuticals Will Present Scientific Data At The Society Of Hospital Medicine Converge 2022

- Half Of IBS Patients Surveyed Report IBS Symptoms More Challenging To Manage In The Past Year

- New Data on Cost Impact of Treating Opioid-Induced Constipation (OIC) with FDA-Approved Medications, Including Salix's RELISTOR^® Subcutaneous Injection (Methylnaltrexone Bromide), in The Emergency Department Is Published in Advances In Therapy

- Salix and Colon Cancer Coalition Join Forces for 'Faces of Blue' Story Series to Raise Awareness of Colorectal Cancer Screenings

- Salix Announces 2022 Gastrointestinal Health Scholars Program

2021

- Relistor^® (Methylnaltrexone Bromide) Data is Published in the Journal of Emergency Medicine

- Salix Brings Educational Resources on Constipation Into the Homes of Patients and Caregivers for Constipation Awareness Month

- Salix Will Share New Rifaximin Data At AASLD's The Liver Meeting™ 2021

- New Report Reveals Barriers To Quality Care For Chronic Liver Disease Patients, A Cause Of Morbidity And Mortality Projected To Grow In The United States

- Salix Will Feature New Data At The American College Of Gastroenterology^® 2021 Annual Scientific Meeting

- Salix Will Share RELISTOR^® (Methylnaltrexone Bromide) Data At The American Society For Pain Management Nursing (ASPMN) 31st National Conference

- Salix Will Share RELISTOR^® (Methylnaltrexone Bromide) Data At PAINWeek 2021

- Salix Announces 2021 Gastrointestinal Health Scholars Program Winners

- Salix Will Share TRULANCE^® (Plecanatide) Data At The 2021 AANP National Conference

- Salix Will Share RELISTOR^® (Methylnaltrexone Bromide) Data Analysis at the 2021 American Society of Clinical Oncology Annual Meeting and 2021 Annual Meeting of the Multinational Association of Supportive Care in Cancer

- Salix Will Feature New Data At Digestive Disease Week^® 2021

- Salix Pharmacetuicals Will Present Scientific Data Featuring Post Hoc Analyses For RELISTOR^® (Methylnaltrexone Bromide) At ASRA's 46th Annual Spring Meeting

- New Report Reveals That More Than One-Third of IBS Patients Surveyed State It Has Been More Challenging To Manage Their Symptoms During The COVID-19 Pandemic

- Salix Launches GastroHub for Advanced Practice Providers, an Educational Website Designed To Provide Nurse Practitioners and Physician Assistants With Relevant Information for Treating IBS-D and HE

- Colon Cancer Coalition and Salix to Launch Year-Long Campaign to Raise Awareness

- Salix Announces 2021 Gastrointestinal Health Scholars Program

2020

- Salix's Methylnaltrexone Abstract Wins Best Of Meeting Award At ASRA's Annual Pain Medicine Meeting

- Salix To Present Data At AASLD's The Liver Meeting Digital Experience

- Bausch Health's Rifaximin Receives FDA Orphan Designation For Sickle Cell Disease

- Salix To Present Data For Products Across Its Portfolio At The American College Of Gastroenterology 2020 Virtual Annual Meeting

- Salix To Present Clinical Data At United European Gastroenterology Week Virtual 2020

- Salix Supports Liver Awareness Month With New Educational Initiatives

- Bausch Health And Alfasigma Announce Resolution Of XIFAXAN^® Intellectual Property Litigation

- Salix Presents Two Methylnaltrexone Scientific Posters At PAINWeek 2020

- Salix Announces Inaugural Salix Gastrointestinal Health Scholars Program Recipients

- Salix To Highlight New Data Across Its Portfolio Of Products At Digestive Disease Week 2020 Virtual Meeting

- Bausch Health Donates Health Care Products And Supplies Through Bausch Foundation In Response To COVID-19 Pandemic

- Bausch Health’s Perspective on COVID-19 (Coronavirus)

2019

- Salix Announces Issuance of an Additional XIFAXAN^® Patent

- Salix Pharmaceuticals Announces Inaugural Scholarship Program To Commemorate Its 30th Anniversary

- Salix Pharmaceuticals to Present New Clinical Data at the American College of Gastroenterology (ACG) Annual Meeting

- Salix Announces Two Methylnaltrexone Poster Presentations For Opioid-Induced Constipation At PAINWeek 2019

- Bausch Health Provides APRISO^® Intellectual Property Litigation Update

- Salix Pharmaceuticals Marks 30-Year Anniversary With Largest Showing Of Data At Digestive Disease Week

- Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease

- Salix Enters Into License Agreement With The University Of California To Develop And Commercialize Novel Compound For The Treatment Of Non-alcoholic Fatty Liver Disease And Non-alcoholic Steatohepatitis

- Salix Announces Poster Presentations for Overt Hepatic Encephalopathy and Opioid-Induced Constipation at Hospital Medicine 2019

- Bausch Health to Acquire Certain Assets of Synergy Pharmaceuticals Inc.

2018

- Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease

- Salix to Present Clinical Data for XIFAXAN^® (RIFAXIMIN) and PLENVU^® at the American College of Gastroenterology Annual Meeting

- Salix Resolves Legacy SEC Investigation With No Penalty

- Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET^® (Avatrombopag)

- Bausch Health Announces Resolution Of XIFAXAN^® Intellectual Property Litigation

- Salix Announces U.S. Launch of PLENVU^®, the First and Only 1-Liter PEG Bowel Cleansing Preparation for Colonoscopies

- US WorldMeds And Salix Pharmaceuticals To Highlight Clinical Data For Opioid Withdrawal Treatment LUCEMYRA^™ (lofexidine) At 2018 PAINWeek Conference

- US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA^™ (lofexidine) 0.18 Mg Tablets

- Salix Expands Microbiome Research And Discovery Through Strategic Collaboration With Cedars-Sinai Medical Center

- Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA^™ (lofexidine)

- Salix To Highlight New Clinical Data During Digestive Disease Week

- Salix Receives FDA Approval For PLENVU^®, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies

- Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR^® Injection

- Arbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration

- Salix Launches ‘Let’s Talk 2’ IBS Awareness Campaign

- Salix provides update on FDA submission for PLENVU^®*

2017

- Salix Announces Filing Acceptance For Plenvu^®* Next Generation Bowel Cleansing Preparation For Colonoscopies

- Statement Regarding Xifaxan Intellectual Property Litigation

- Valeant Pharmaceuticals Corrects Misleading Report About Salix Investigation

- Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity

2016

- Valeant Announces The Initiation Of A Primary Care Sales Force For Xifaxan^® And Relistor^®

- Valeant Pharmaceuticals Comments On Press Report Regarding Its Gastroenterology Business Unit

- Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor^® Tablets

- Valeant Pharmaceuticals Announces Licensing Agreement With Norgine B.V. For NER1006 In U.S. And Canada

- Valeant and Progenics Announce FDA Approves RELISTOR^® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain

- Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR